📉 This integrates contract research and manufacturing services, reducing inefficiencies.
🧬 The findings suggest significant time and cost savings for cancer treatments, benefiting patients and improving returns for developers.
🔬 Over 120 biotech companies have partnered with Thermo Fisher on various projects.
Introduction:
The article discusses a significant study conducted by Thermo Fisher Scientific in collaboration with the Tufts Center for the Study of Drug Development, which demonstrates that the integrated Accelerator™ Drug Development platform can substantially reduce the development timelines for oncology drugs.
- Thermo Fisher’s Accelerator™ can decrease the time oncology drug candidates spend in clinical trials by up to 34 months, addressing a prolonged development process typically spanning 10 to 15 years.
- The research, highlighted in a peer-reviewed white paper, suggests that consolidation of contract research and manufacturing services leads to improved efficiency and cost-effectiveness.
- The study identifies operational inefficiencies and “white space” periods between clinical trial phases as critical areas for time savings when utilizing an integrated service model.
- Financial analysis within the white paper reveals substantial economic benefits, including potential return on investment (RoI) ranging from 0.2 to 113 times the initial input for various drug phases.
- Thermo Fisher’s continued investment in R&D and manufacturing capabilities, along with primary expansions in biomanufacturing, emphasizes a commitment to enhance the efficiency of drug development processes.
Conclusion:
The findings from this study underline the importance of integrated service platforms like Thermo Fisher’s Accelerator™ in modern drug development, particularly for oncology treatments. Acknowledging operational inefficiencies and prioritizing streamlined processes can lead to significant time and cost savings, ultimately facilitating faster patient access to groundbreaking therapies. Moving forward, the emphasis on service integration is likely to shape future frameworks in biopharma’s approach to drug development and manufacturing.
